BLLN
Get informed when a big investor buys or sells
+ FollowUndervalued by 1.9% based on the discounted cash flow analysis.
| Market cap | $4.87 Billion |
|---|---|
| Enterprise Value | $4.47 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.06 |
| Beta | 0.34 |
| Outstanding Shares | 46,403,350 |
| P/E Ratio | 153.49 |
|---|---|
| PEG | -4.55 |
| Price to Sales | 14.3 |
| Price to Book Ratio | 10.4 |
| Enterprise Value to Revenue | 11.25 |
| Enterprise Value to EBIT | 108.24 |
| Enterprise Value to Net Income | 133 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.27 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.1130▼ 135.85% |
|---|---|
| Total Calls | 71,700▲ 271.50% |
| Total Puts | 79,800▲ 67.30% |
Holdings and activity of institutional investors.
| Ownership % | 33.18%▲ 8.49% |
|---|---|
| Total Invested | $1.83B▲ 109.65% |
| Investors Holding | 164▲ 70.00% |
No data
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to...